Evidence map›Paper›PMID 39952925›Full record

ArticleNature communications2025

Structural insights into human brachyury DNA recognition and discovery of progressible binders for cancer therapy.

Joseph A Newman, Angeline E Gavard, Nergis Imprachim, Hazel Aitkenhead, Hadley E Sheppard, Robert Te Poele, Paul A Clarke, Mohammad Anwar Hossain, Louisa Temme, Hans J Oh and 5 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Joseph A NewmanCentre for Medicines Discovery, University of Oxford, Oxford, UK. Joseph.newman@cmd.ox.ac.uk.ORCID http://orcid.org/0000-0003-4488-0516
Angeline E GavardCentre for Medicines Discovery, University of Oxford, Oxford, UK.
Nergis ImprachimCentre for Medicines Discovery, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-5167-3203
Hazel AitkenheadCentre for Medicines Discovery, University of Oxford, Oxford, UK.
Hadley E SheppardCentre for Cancer Drug Discovery, The Institute of Cancer Research, London, UK.
Robert Te PoeleCentre for Cancer Drug Discovery, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0009-0001-3596-6572
Paul A ClarkeCentre for Cancer Drug Discovery, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0001-9342-1290
Mohammad Anwar HossainSGC-UNC, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0001-8684-8755
Louisa TemmeSGC-UNC, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Hans J OhSGC-UNC, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0009-0007-2354-080X
Carrow I WellsSGC-UNC, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0003-4799-6792
Zachary W Davis-GilbertSGC-UNC, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Paul WorkmanCentre for Cancer Drug Discovery, The Institute of Cancer Research, London, UK. paul.workman@icr.ac.uk.ORCID http://orcid.org/0000-0003-1659-3034
Opher GileadiCentre for Medicines Discovery, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-6886-898X
David H DrewrySGC-UNC, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. david.drewry@unc.edu.ORCID http://orcid.org/0000-0001-5973-5798

Funding

Transcription-Coupled & Replication-Associated Excision RepairP01CA092584 · NCI · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI John A. Tainer · 2001 to 2026
$89.6M
NCI NIH HHS P01 CA092584Wellcome Trust
6 · The paper itself

Abstract

Brachyury is a transcription factor that plays an essential role in tumour growth of the rare bone cancer chordoma and is implicated in other solid tumours. Brachyury is minimally expressed in healthy tissues, making it a potential therapeutic target. Unfortunately, as a ligandless transcription factor, brachyury has historically been considered undruggable. To investigate direct targeting of brachyury by small molecules, we determine the structure of human brachyury both alone and in complex with DNA. The structures provide insights into DNA binding and the context of the chordoma associated G177D variant. We use crystallographic fragment screening to identify hotspots on numerous pockets on the brachyury surface. Finally, we perform follow-up chemistry on fragment hits and describe the progression of a thiazole chemical series into binders with low µM potency. Thus we show that brachyury is ligandable and provide an example of how crystallographic fragment screening may be used to target protein classes that are difficult to address using other approaches.

Indexed as

ChordomaDNAFetal ProteinsT-Box Domain ProteinsBinding SitesBone NeoplasmsBrachyury ProteinCrystallography, X-RayHumansLigandsModels, MolecularProtein BindingThiazolesBrachyury ProteinDNAFetal ProteinsLigandsT-Box Domain ProteinsThiazoles

Identifiers

PMID39952925
PMCPMC11828899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.